1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18618
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHess, K. R.en
dc.contributor.authorWong, E. T.en
dc.contributor.authorJaeckle, K. A.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorLevin, V. A.en
dc.contributor.authorPrados, M. D.en
dc.contributor.authorYung, W. K.en
dc.date.accessioned2015-11-24T18:53:52Z-
dc.date.available2015-11-24T18:53:52Z-
dc.identifier.issn1522-8517-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18618-
dc.rightsDefault Licence-
dc.subjectActuarial Analysisen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectAstrocytoma/drug therapy/mortality/radiotherapyen
dc.subjectBrain Neoplasms/*drug therapy/mortality/radiotherapyen
dc.subjectCarboplatin/administration & dosageen
dc.subjectCombined Modality Therapyen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectEflornithine/administration & dosageen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectGlioblastoma/drug therapy/mortality/radiotherapyen
dc.subjectGlioma/*drug therapy/mortality/radiotherapyen
dc.subjectHumansen
dc.subjectInterferon-beta/administration & dosageen
dc.subjectMaleen
dc.subjectMenogaril/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Local/*drug therapy/mortalityen
dc.subjectProcarbazine/administration & dosageen
dc.subjectPrognosisen
dc.subjectProportional Hazards Modelsen
dc.subjectTexas/epidemiologyen
dc.subjectTreatment Outcomeen
dc.subjectTretinoin/administration & dosageen
dc.titleResponse and progression in recurrent malignant gliomaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11550320-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1999-
heal.abstractIn this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.en
heal.journalNameNeuro Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons